

### **Amendments to the Specification**

Please insert the following as the first paragraph beneath the title on page one of the specification.

**This application is the National Stage of Application No. PCT/EP2004/008848, filed on August 6, 2004, which claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 60/493,828, filed August 8, 2003. The contents of both are incorporated herein by reference in their entirety.**

Please insert the following text as the Abstract:

#### **Abstract**

The present invention relates to a method of treating myelodysplastic syndromes, lymphomas and leukemias, and also solid tumors with a pharmaceutical combination of a FLT-3 kinase inhibitor and a histone deacetylase inhibitor (HDAI). It also relates to the use of a pharmaceutical combination of a histone deacetylase inhibitor and a FLT-3 kinase inhibitor for the treatment of the diseases or malignancies mentioned above and the use of such a pharmaceutical composition for the manufacture of a medicament for the treatment of these diseases or malignancies.

The Abstract is submitted herewith on a separate sheet appended hereto and should be inserted in the specification following the Claims